 | Up a level |
Porter, J.B. and Elalfy, M. and Taher, A.T. and Chan, L.L. and Lee, S.H. and Sutcharitchan, P. and Aydinok, Y. and Chakravarty, S. and El-Ali, A. and El-Beshlawy, A. (2014) Insights into relationships between serum ferritin and liver iron concentration trends during 12 months of iron chelation therapy with deferasirox - a post-hoc analysis from the epic study. Blood, 124 (21).
Pennell, D. and Porter, J.B. and Cappellini, M.D. and Chan, L.L. and El-Beshlawy, A. and Aydinok, Y. and Ibrahim, H. and Li, Chi-Kong and Viprakasit, V. and Elalfy, M.S. and Kattamis, A. and Smith, G. and Habr, D. and Domokos, G. and Roubert, B. and Taher, A. (2010) Continued improvement and normalization of myocardial T2*in patients with beta-thalassemia major treated with deferasirox (Exjade (R)) for up to 3 years. Blood, 116 (21). pp. 1735-1736.
Pennell, D.J. and Porter, J.B. and Cappellini, M.D. and El-Beshlawy, A. and Chan, L.L. and Aydinok, Y. and Elalfy, M.S. and Sutcharitchan, P. and Li, C.K. and Ibrahim, H. and Viprakasit, V. and Kattamis, A. and Smith, G. and Habr, D. and Domokos, G. and Roubert, B. and Taher, A. (2010) Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood, 115 (12). pp. 2364-2371.
